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Abstract Serotonin emerges as crucial neurotransmitter and
hormone in a growing number of different physiologic
processes. Besides extensive serotonin production previously
noted in patients with metastatic carcinoid tumors, serotonin
now is implicated in liver cell regeneration and bone
formation. The aim was to develop a rapid, sensitive, and
highly selective automated on-line solid-phase extraction
method coupled to high-performance liquid chromatogra-
phy–tandem mass spectrometry (XLC-MS/MS) to quantify
low serotonin concentrations in matrices such as platelet-poor
plasma and urine. Fifty microliters plasma or 2.5 μLu r i n e
equivalentwerepre-purifiedbyautomatedon-linesolid-phase
extraction, using weak cation exchange. Chromatography of
serotonin and its deuterated internal standard was performed
with hydrophilic interaction chromatography. Mass spectro-
metric detection was operated in multiple reaction monitoring
mode using a quadrupole tandem mass spectrometer with
positive electrospray ionization. Serotonin concentrations
were determined in platelet-poor plasma of metastatic
carcinoid patients (n=23) and healthy controls (n=22).
Urinary reference intervals were set by analyzing 24-h urine
collections of 120 healthy subjects. Total run-time was 6 min.
Intra- and inter-assay analytical variation were <10%.
Linearity in the 0–7300 μmol/L calibration range was
excellent (R
2>0.99). Quantification limits were 30 and
0.9 nmol/L in urine and plasma, respectively. Platelet-poor
serotonin concentrations in metastatic carcinoid patients were
significantly higher than in controls. The urinary reference
interval was 10–78 μmol/mol creatinine. Serotonin analysis
with sensitive and specific XLC-MS/MS overcomes limi-
tations of conventional HPLC. This enables accurate
quantification of serotonin for both routine diagnostic
procedures and research in serotonin-related disorders.
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Abbreviations
5-HT 5-Hydroxytryptamine (serotonin)
XLC-MS/
MS
On-line solid-phase extraction–high-performance
liquid chromatography–tandem mass spectrometry
SPE Solid-phase extraction
HPLC High-performance liquid chromatography
MS/MS Tandem mass spectrometry
5-HT-d4 Deuterium-labeled serotonin
Introduction
Serotonin (5-HT: 5-hydroxytryptamine) is synthesized from
the essential amino acid tryptophan in the enterochromaffin
cells of the gut and in serotonergic neurons in the central
nervous system. The major part of dietary tryptophan is used
forproteinsynthesis,whileabout2%ofthedietarytryptophan
is used for the serotonin production. Serotonin is stored
predominantly (about 80%) in the enterochromaffin cells of
the gastrointestinal tract, in the dense granules of platelets and
in the serotonergic neurons of the central nervous system [1–
3]. Peripheral serotonin is metabolized mainly in the lung
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oxidase-A (MAO-A; EC 1.4.3.4), resulting in urinary
excretion of 5-hydroxyindole-3-acetic acid (5-HIAA) [3].
Serotonin is a neurotransmitter involved in CNS neuro-
transmission processes, but also emerges as a crucial
hormone in a growing number of different physiologic
processes outside the brain. Depletion of serotonin is
implicated in liver cell regeneration [4], bone formation
and psychiatric diseases [5–8], while extensive serotonin
production has been noted in carcinoid tumors [5, 9, 10].
Depending on the site of origin, carcinoid tumors can give
rise to excessive synthesis, storage, and release of seroto-
nin; its precursor, 5-hydroxytryptophan (5-HTP); and its
major metabolite, 5-HIAA. For the clinical chemical
diagnosis and follow-up of patients with carcinoid tumors,
measurements of serotonin, its precursors and its metabo-
lites in body fluids and tissues are used.
In previous studies, we showed that platelet serotonin is
the most accurate marker for the diagnosis of carcinoids
[11, 12]. In healthy subjects, but not in carcinoid patients,
99% of circulatory serotonin is accumulated and stored in
platelets. Therefore, the measurement of the free serotonin
concentration in platelet-poor plasma might provide infor-
mation about the level of serotonin overproduction which is
of clinical relevance for carcinoid patients, since the free
fraction is the serotonin pool that actually binds to the
serotonin receptor and exerts its actions.
Normally, circulating serotonin is almost entirely confined
to platelets. Due to its low concentrations and the resulting
analytical detectability problems, free plasma serotonin has
not been measured routinely. 5-HIAA in urine is used for
follow-up of carcinoid patients. It reflects best the tumor
burden as it is the metabolic end product resulting from free
and stored serotonin turnover. Urinary serotonin is less
important, but is considered to reflect clearance of plasma
free serotonin and renal decarboxylated 5-hydroxytryptophan
(5-HTP) [13, 14]. Quantification can however be useful in
the diagnosis of midgut and aromatic amino acid decar-
boxlyase (AADC)-deficient foregut carcinoids [9, 11, 13,
15]. In previous studies, it was noted that some of these
tumors cannot produce serotonin, because of a deficiency in
the enzyme AADC responsible for the conversion of 5-HTP
to serotonin. In these cases, some 5-HTP can be decarboxy-
lated by the kidney and thus excreted in the urine as
serotonin. Urinary serotonin measurement was therefore
considered to be a useful marker in the diagnosis of
AADC-deficient carcinoid [13].
Several analytical techniques have been developed for the
measurement of serotonin and its related compounds. HPLC-
based techniques are commonly used [12, 16] and easily
coupled to mass spectrometric detectors to increase analytical
sensitivity and specificity and reduce the chance of interfer-
ences. In addition, automation of sample pre-treatment is
emerging [17, 18], since it enables the reduction of analytical
variation attributable to differences in manual sample pre-
treatment and, moreover, decreases analysis turnaround time.
In order to enable quantification of serotonin in platelet-
poor plasma and to replace the laborious, currently used
method for urinary serotonin, we developed an automated
on-line solid-phase extraction–liquid chromatographic
method with tandem mass spectrometric detection (XLC-
MS/MS) for the measurement of serotonin. This method
combines selective and specific liquid chromatographic–
tandem mass spectrometry with on-line solid-phase extrac-
tion (SPE) and uses similar analytical principles as
previously described for plasma metanephrines analysis
[19]. With this technique, we quantified plasma free
serotonin in 22 healthy controls and 23 carcinoid patients
and established the reference interval for urinary serotonin
excretion in 24-h urine collections in 120 healthy subjects.
Experimental
Chemicals and reagents
HPLC-grade acetonitrile was obtained from Rathburn Chem-
icals Ltd. (Walkerburn, UK); ammonium formate 99.995
+%
from Sigma-Aldrich Ltd. (Steinheim, Germany); formic acid
98% to 100% ultrapure from BDH Laboratory Supplies
(Poole, UK); sodium hydroxide (NaOH), hydrochloric acid
and urine preservatives ascorbic acid and EDTA were
acquired from Merck KGaA (Darmstadt, Germany).
Serotonin was purchased from Sigma-Aldrich Ltd. and
serotonine-α,α,β,β-d4creatininesulfatecomplexfromC/D/N
Isotopes Inc. (Pointe-Claire, Quebec, Canada); Reagent-grade
water,obtainedfrom a Barnsteadsystem,was usedthroughout
the study procedure. All chemicals and solvents were of
analytical-reagent-grade.
Instruments
A Spark Holland Symbiosis® on-line SPE system (Spark
Holland, Emmen, the Netherlands) was used for all analyses.
The system consists of a temperature-controlled autosampler
(temperature maintained at 10 °C), a SPE controller unit
(automated cartridge exchanger or ACE), a solvent delivery
unit (two high-pressure dispensers), and an HPLC pump, as
shown previously [19, 20]. The ACE module contains two
connectable six-way valves and a SPE cartridge-exchange
module. The high-pressure dispensers provide SPE car-
tridges with solvents for conditioning, equilibration, sample
application, and clean-up. The integrated HPLC pump was a
binary high-pressure gradient pump. Column temperature
was controlled with a Mistral Column Oven (Spark
Holland). Detection was performed with a Quattro® Premier
2610 W.H.A. de Jong et al.tandem mass spectrometer equipped with a Z Spray® ion
source operated in positive electrospray ionization mode
(Waters, Milford, MA). All aspects of system operation and
data acquisition were controlled using MassLynx v4.1
software with automated data processing using the Quan-
Lynx Application Manager (Waters).
Biological samples
For method-comparison studies, urine samples with a con-
centration range up to 4,240 μmol/L were used from 60
patients withsuspected orknown metastaticcarcinoidtumors.
The reference interval for urinary free serotonin was obtained
from the analysis of 24-h urine collections of 120 healthy
subjects, participating in the LifeLines study (24). The
reference interval was calculated with EP Evaluator™
software [21] as recommended by the Clinical and Labora-
tory Standards Institute (CLSI) according to CLSI C28-A2
[22]. LifeLines is a multi-disciplinary prospective
population-based cohort study examining in a unique three-
generation design the health and health-related behaviors of
165,000 persons living in the North East region of The
Netherlands. It employs a broad range of investigative
procedures in assessing the biomedical, socio-demographic,
behavioral, physical, and psychological factors which con-
tribute to the health and disease of the general population,
with a special focus on multimorbidity. In addition, the
LifeLines project comprises a number of cross-sectional sub-
studies which investigate specific age-related conditions.
These include investigations into metabolic and hormonal
diseases, including obesity, cardiovascular and renal dis-
eases, pulmonary diseases and allergy, cognitive function
and depression, and musculoskeletal conditions.
Plasma free serotonin levels were determined in a
prospective pilot study of 22 healthy controls and 15
patients with a metastatic serotonin-producing carcinoid
tumor [23], which was extended with eight patients to a
total of 23 carcinoid patients. Blood for platelet-poor
plasma was obtained by venipuncture using a butterfly
needle to collect in 5 mL plastic syringes containing 60 μL
7.5% K3EDTA solution. Blood was centrifuged within
30 min after drawing at 12,000×g f o r2m i ni na n
Eppendorf Microcentrifuge at 22 °C [24]. The remaining
plasma was stored at −80 °C until analysis. The studies
were approved by the medical ethical committee of our
institution and conducted in accordance with the guidelines
of the Declaration of Helsinki. All participants gave written
informed consent.
Sample preparation
Working solutions of serotonin were diluted from a freshly
weighed stock solution (1 mg/mL) on the day of analysis.
Working solutions of serotonin-d4 (1 μM) were diluted from
the stock solution (0.4 mg/mL in 0.04 M ascorbic acid) that
was stored at −20 °C for 6 months. Aqueous calibrators were
prepared by addition of working solution corresponding to
concentrations from 30 to 7,300 nmol/L serotonin for urinary
analysis and from 3.49 to 4900 nmol/L for plasma. All
solutions were prepared in water with ascorbic acid added as
preservative (400 mg/L). Urinary calibration curves were
aqueous. Plasma calibration curves were made using blank
plasma, obtained by dialysis. Low, medium, and high
quality-control samples were made by pooling urine and
plasma from healthy subjects and carcinoid patients for
diagnostic procedures available at our laboratory. Urine
samples were stored at −20 °C until analysis, platelet-poor
plasma samples at −80 °C.
Fifty microliters of urine (acidified with HCl to pH 4 and
containing the conservatives ascorbic acid and EDTA (1:1
w/w), added prior to collection) or 500 μL of plasma was
mixed directly in an autosampler vial with 100 μL internal
standard solution (final concentration 1800 nmol/L for
urine and 80 nmol/L for plasma). Urine samples were
diluted with 0.2 M phosphate buffer (pH 7) in ascorbic acid
solution and plasma samples with ascorbic acid solution to
reach a final volume of 1 mL. Fifty microliters (urine sample)
or 100 μL (plasma) was injected into the XLC-MS/MS
system. This injection volume was equivalent to 2.5 µL of
urine and 50 μLp l a s m a .
On-line SPE
Sample clean-up took place by on-line SPE, following a
similar procedure as described previously for the structure
related metanephrines [19]. Oasis® WCX (weak cation
exchange) 10 by 1 mm SPE cartridges (Waters Corp.) were
used for sample extraction. The Symbiosis® system was
designed to proceed automatically through a series of
programmable routines during which the SPE cartridge is
loaded, washed, and eluted by solvents delivered by two
high-pressure dispensers (HPD1 and HPD2). Serotonin was
eluted directly on the analytical column by LC gradient
elution (600 μL of mobile phase). Processing of subsequent
samples was carried out in parallel and cartridges were
regenerated.
Liquid chromatography
Chromatographic separationwasachievedby using anAtlantis
HILIC Silica column (particle size 3 μm, 2.1 mm internal
diameter by 50 mm; Waters). A gradient flow of 100 mmol/L
ammonium formate in water adjusted to pH 3.0 with formic
acid (A) and acetonitrile (B; flow rate 0.40 mL/min) was
applied to the chromatographic column (Table 1). Gradients
applied were linear. Column temperature was kept at 25 °C.
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The mass spectrometer was directly coupled to the
chromatographic column. In positive electrospray ioniza-
tion mode, serotonin and its deuterated internal standard
were protonated to produce ions at the form [M+H]
+, with
m/z 177 and m/z 181, respectively. Upon collision-induced
dissociation (CID) with argon gas, these precursor ions
produced characteristic product ions of m/z 160 [M-NH2]
and 132 [M-C2H4NH2] and 115 [M-C2H4NH2OH] for
serotonin and m/z 164, 136, and 119 for the deuterated
internal standard. A multiple reaction monitoring mode
(MRM) was developed for the specific m/z transitions
177→160, 177→132 and 177→115 (serotonin) and
181→164, 181→136 and 181→119 (internal standard)
using a dwell time of 0.05 s and an interchannel delay of
20 ms. The second and third mass transitions were used as
qualifiers, following EU directive 2002/657/EC.
Statistics
For method comparison of the urinary serotonin, Deming
regression analysis was applied.
Student’s T test was applied for comparison of mean
platelet-poor plasma serotonin levels in healthy controls
and carcinoid patients (SPSS version 14).
Results
Chromatography
Total cycle time per sample, including extraction, was
6 min. Serotonin and its deuterated internal standard co-
eluted after 2.8 min. The identity of the compound was
confirmed by the specific mass spectrum. In Fig. 1 mass
chromatograms are shown of urine and platelet-poor plasma
samples from a healthy subject (A and C) and from a
carcinoid patient (B and D). Ion suppression was examined
Table 1 Gradient elution scheme liquid chromatography
Time (mm:ss) Flow (mL/min) Solvent A% Solvent B %
00:01 0.30 5 95
01:30 0.30 20 80
03:30 0.30 20 80
04:00 0.30 5 95
06:00 0.30 5 95
Solvent A 100 mM ammonium formate pH 3, Solvent B acetonitrile
Fig. 1 Chromatograms of serotonin in urine and plasma samples from
healthy controls and carcinoid patients, obtained by XLC-MS/MS
analysis. Chromatograms are obtained by on-line solid-phase extrac-
tion using weak cation exchange coupled to hydrophilic interaction
liquid chromatography with tandem mass spectrometric detection. The
mass chromatograms show the mass transitions of 177→160 (5-HT)
and 181→164 (deuterated internal standard 5-HT-d4). Retention time
of serotonin is 2.8 min. Responses are normalized to 100%. a Urinary
sample of a healthy control (32.4 μmol/mol creatinine), d0 area 8542,
d4 area 42163. b Urinary sample of carcinoid patient (718.5 μmol/mol
creatinine), d0 area 541167, d4 area 81340. c Plasma sample of a
healthy control (4.2 nmol/L), d0 area 5181, d4 area 73091. d Plasma
sample of a carcinoid patient (289.4 nmol/L), d0 area 213186, d4 area
43549. 5-HT serotonin, 5-HT-d4 deuterated serotonin
2612 W.H.A. de Jong et al.by direct infusion of the analytes in the mass spectrometer
with simultaneous injection of a blank sample and
biological plasma and urine samples and was not observed
for plasma or urine (data not shown).
Detection limits
The limit of quantification (S/N 10:1) was 0.03 μmol/L
with a CV of 5.4% (n=20) in urine and 0.9 nmol/L with a
CV of 9.0% (n=20) in plasma.
Linearity and precision
For urine analysis, aqueous calibration curves in a
concentration range from 0.3–7300 μmol/L (n=8) showed
excellent linearity. The mean slope was 0.4916, intercept
was 0.0075 μmol/L and correlation coefficient was 0.99.
Spiked urine calibration curve gave a comparable slope
(0.4747), but a different intercept (0.1145 μmol/L), because
of the endogen basal serotonin concentration present in
pooled urine, which confirms the selectivity of the method.
Inter-assay linearity (n=18) obtained over a concentra-
tion range from 3.5–4,900 nmol/L serotonin in blank
plasma was also excellent. The mean slope was 0.00165,
with no significant intercept and a correlation coefficient of
0.99. An aqueous calibration curve gave a comparable
slope. Intra-assay precision was determined by replicate
analyses in a single run at three concentrations (n=20).
Inter-assay was determined by analysis of three concen-
trations over 8 weeks (n=20). For low, medium, and high
concentrations in both urine and plasma CVs were <10%.
Intra-assay CVs were 2.6–3.4% in urine and 1.6–7.5% in
plasma. Inter-assay CVs were 2.8–10% in urine and 4.1–
7.9% in plasma. Precision data are shown in Table 2.
Samples with high serotonin concentrations that exceed the
calibration range can be diluted up to 50 times, which
results in comparable outcomes.
Recovery and stability
Recovery experiments were conducted with spiked standard
addition in three concentrations (low, medium, high)
measured with and without solid-phase extraction. Recov-
eries ranged from 88–135% in both urine and plasma.
Absolute recovery on the SPE cartridge was measured with
spiked urine samples in the same concentration ranges.
These recoveries ranged from 41–74% in plasma and 83–
85% in urine.
Samples, containing preservatives as described above,
were found to be stable during three freeze–thaw cycles in
both urine and plasma. Plasma samples were stable to a
maximum of 2 days at 5 °C in the dark (autosampler), and
urine samples for only 8 h. Cartridges can be reused 3 times
for urine samples and up to 15 times for plasma with
consistent results and without occurrence of carry-over
according to the EP10-A3 protocol of the Clinical and
Laboratory Standards Institute [22].
Biological samples
The new XLC-MS/MS method correlated with the
former conventional HPLC method [16] with a correla-
tion coefficient of 0.9789 (Fig. 2). The regression equation
for the XLC-MS/MS method (y) and the HPLC method (x)
had a slope of 1.093 (±0.059) and an intercept of 0.081
(±0.062) μmol.
Table 2 Intra- and inter-assay imprecision of serotonin analysis with XLC-MS/MS
Mean analytical variation in urine
Intra-assay (n=20) Inter-assay (n=15)
Mean SD CV (%) Mean SD CV (%)
(μmol/mol
creatinine)
(nmol/L) (μmol/mol
creatinine)
(nmol/L) (μmol/mol
creatinine)
(nmol/L) (μmol/mol
creatinine)
(nmol/L)
Urine
Low 0.5 0.01 2.6 0.6 0.06 10.0
Medium 2.1 0.07 3.3 1.9 0.20 9.9
High 5.0 0.20 3.4 4.9 0.14 2.8
Plasma
Low 5.3 0.40 7.5 5.6 0.44 7.9
Medium 174.2 2.85 1.6 165.9 8.51 5.1
High 1120.9 20.93 1.9 1083.8 44.9 4.1
Analytical variation was calculated by measuring each sample 20 times per day (intra-assay) and in 20 different assays (inter-assay)
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the 120 healthy subjects was normal (Fig. 3) and the
reference interval was 10–78 μmol/mol creatinine.
Free plasma serotonin concentrations were significantly
higherin carcinoid patients(mean concentration60.8nmol/L)
than in healthy controls (mean concentration 4.6 nmol/L) (P<
0.001; Fig. 4).
Discussion
This study demonstrates that plasma and urinary serotonin
can be measured selective, specific and sensitive with an
automated on-line solid-phase extraction–liquid chromato-
graphic method with tandem mass spectrometric detection
(XLC-MS/MS). The urinary reference interval was in
agreement with previous results [11, 25].
The method is based on similar analytical principles as
our previously described method for the analysis of the
structurally related plasma metanephrines [19]: solid-phase
Fig. 4 Free serotonin concentrations in healthy controls (n=22) and
metastatic serotonin-producing carcinoid patients (n=23). Each dot
represents a subject. Concentrations are expressed as the natural
logarithm (ln) of nanomoles per liter units, to obtain normal
distributions. Horizontal lines indicate mean concentrations. Mean
free serotonin concentrations, measured in platelet-poor plasma, are
4.6 nmol/L for healthy controls and 60.8 nmol/L for carcinoid
patients. Mean serotonin concentrations in the carcinoids patients are
higher than in the healthy controls (P<0.001)
Fig. 3 Distribution of urinary serotonin concentrations in reference
samples from 120 healthy individuals in μmol/mol creatinine. a The
distribution of individual serotonin concentrations is shown in a
histogram with a mean concentration of 38.2 μmol/mol creatinine.
The black line shows a normal distribution which is in correspondence
with the distribution of the individual serotonin concentrations. b
Probability plot of the distribution of individual serotonin concen-
trations indicating normal distribution of the concentrations
Fig. 2 Correlation between the new (y XLC-MS/MS) and the old (x
HPLC-fluorometric detection) method for the measurement of
serotonin in urine. The black line is the Deming regression scatter
plot for the correlation between XLC-MS/MS and HPLC with
equation y=0.081+1.093x and a correlation coefficient of 0.97. The
gray line shows the ideal correlation between the two methods with
the equation y=x
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philic interaction chromatography. Major limitations of the
regularly used conventional HPLC method with fluoromet-
ric detection [26] for the diagnosis of fore- and midgut
carcinoid tumors include the long sample preparation time
and the use of a non-isotope-labeled internal standard. The
newly developed automated method with MS/MS detection
is, in addition, more specific because of the selection of the
precursor to product mass transition, which enables
identification of the analyte. Furthermore, MS/MS allows
the use of a stable isotope-labeled internal standard, while
time for chromatographic separation can be reduced. Main
advantages of the automated sample preparation are ease of
handling, portability, and reduction of cost per sample,
because of reduced sample preparation time, high throughput,
cheapercartridges,andreuseofcartridges.Furthermore,intra-
and inter-assay variations are reduced, which increases the
reproducibility of results. LC-MS/MS methods without
automated sample preparation [27, 28] have sensitivities
and specificities that can be compared with the XLC-MS/MS
method described here and are increased when compared to
conventional HPLC techniques. The supplementary advan-
tage compared to other LC-MS/MS methods is that our
method is completely automated, which means a great
reduction in total analysis time including sample clean-up.
Specific sample preparation chemistry with weak cation
exchange for clean-up and chromatographic separation with
HILIC result in optimal analysis conditions.
In addition, this study demonstrated that the low physio-
logicalserotoninlevelsinplatelet-poorplasmacanberoutinely
measured with a more specific and sensitive method than
before [25, 29]. LLOQ for plasma serotonin has been reduced
70 times at our laboratory, enabling measurement of free
s e r o t o n i ni nh e a l t h yp e r s o n s .T h i sr e s u l t e di nac o m p a r i s o n
between carcinoid patients and healthy controls with the
outcome that in carcinoid patients, free serotonin was 13-fold
higher (P<0.001) than in healthy controls. High concen-
trations can be hazardous in the body and result in heart valve
damage and vasoactivity-related symptoms as diarrhea,
flushing, and bronchoconstriction [5]. Contamination of the
low platelet-poor concentrations with the high platelet-stored
amount of serotonin has to be avoided. Therefore, pre-
analytical factors are of importance for the measurement of
serotonin in platelet-poor plasma [5, 24] and serotonin levels
in this specific blood fraction are not consistent for healthy
subjects. Our results for healthy controls are in agreement
with those determined with a similar blood sampling and
sample pre-treatment method [24], although less careful
collection and centrifugation [25] result in higher concen-
trations. Carcinoid patients have shown elevated concentra-
tions previously, as in our results [25].
In order to investigate the recently uncovered role of
serotonin as a peripheral hormone in processes such as liver
cell regeneration [4], valvular heart disease [30] and bone
formation in laboratory animals [8, 31], it will be important
to clarify the role of factors influencing the free serotonin
fraction. The serotonin transporter, which is responsible for
inward transport of free serotonin, shows considerable
genetic variation, causing different levels of expression.
Commonly prescribed medication such as selective seroto-
nin reuptake inhibitors (SSRIs), influence serotonin avail-
ability by interfering with its metabolic clearance and
uptake as a consequence of the blocking of the serotonin
transporter [6, 32]. The role of serotonin in the development
of osteoporosis and bone formation has been associated
with the use of those SSRIs [8, 31]. During SSRI use and in
patients with osteoporosis free serotonin levels are currently
unknown, but should be measured in the future to
investigate its role in the development and the treatment
of osteoporosis.
Conclusion
Automated on-line XLC-MS/MS enables the quantification
of serotonin in both urine and plasma samples. This method
overcomes the limitations of existing manual HPLC
procedures, especially with regard to interference and hands
on analysis time. Due to the high sensitivity and specificity,
low free serotonin levels in platelet-poor plasma can be
measured routinely, enabling to investigate its role in
serotonin-related disorders.
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